Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Analysts following Egetis


Bryan, Garnier & Co: Oscar Haffen Lamm

Rx Securities: Joseph Hedden

Carnegie: Arvid Necander

Pareto Securities: Chien-Hsun Lee

ABG Sundal Collier: Alexander Krämer

Redeye: Fredrik Thor






Calendar and upcoming reports

August 22, 2024
Interim Report Q2 2024 (7:00am CEST)

November 8, 2024
Interim Report Q3 2024 (7:00am CET)

Show more events



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10